Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has now added to the list of available treatments at its Ontario clinic.
On Monday, the company announced that it would now be offering ketamine-assisted therapy for patients with neurologic conditions at its wholly-owned facility, the Neurology Centre of Toronto (NCT).
NCT is primarily concerned with treating concussions and brain injuries, epilepsy and functional neurological disorders. The facility has a team of over 20 specialists that offer a broad range of services and supportive therapies.
Read more: Numinus reports sequential revenue dip of 5.7%
Read more: Numinus to offer ketamine-assisted psychotherapy
“Following a thorough evaluation, Numinus found NCT’s existing infrastructure, client base and practitioners to be highly suitable for offering ketamine-assisted therapy. Mental health challenges are commonly associated with neurologic diagnoses and ketamine-assisted therapy is a promising tool that we now have available for our patients,” said Dr. Evan Lewis (MD), vice president of psychedelic neurology at Numinus.
“The use of ketamine-assisted therapy within the field of neurology is novel, and we look forward to expanding access for our patients and contributing to the body of knowledge regarding ketamine applications.”
The new service offered at NCT will follow pre-existing company protocol for ketamine therapy with some modifications for patients with neurologic conditions. The company has locations in Canada and the U.S. that also offer ketamine-assisted therapy. Numinus also says that a group of existing patients have been reviewed as candidates for the clinic’s new treatment and more patients will follow after evaluation of the initial group.
NCT is also planning to broaden its capabilities in order to help support applications for other varieties of psychedelic therapy through the Special Access Program (SAP) from Health Canada. The company says a successful SAP application was recently completed in Montreal by a Numinus physician to offer psilocybin-assisted therapy for the treatment of depression.
“We look forward to making psychedelic-assisted therapies more accessible to those in need in Ontario through ketamine-assisted therapy and Special Access Program applications,” said Payton Nyquvest, CEO and founder of Numinus.
“Our patients often face complex challenges, including comorbid neurologic and mental health disorders. By offering these additional services, we can help alleviate their distress and improve their quality of life.”
